Pharmacogenomics of Adrenergic Receptors; from Hypertension to Heart Failure
Shinpei Nonen1, Junichi Azuma2, Yasushi Fujio1, *
Identifiers and Pagination:Year: 2010
First Page: 14
Last Page: 20
Publisher Id: TOHYPERJ-3-14
Article History:Received Date: 02/02/2010
Revision Received Date: 15/07/2010
Acceptance Date: 07/08/2010
Electronic publication date: 28/9/2010
Collection year: 2010
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cardiovascular medicine is a leading area of pharmacogenomics (PGx). A number of PGx studies have linked genetic polymorphisms to patients’ response to the drugs in the pharmacotherapy against cardiovascular diseases. Among them, PGx of adrenoceptors is one of the most important fields, because adrenergic networks play important roles in cardiovascular systems. The excess of adrenergic stimuli result in cardiovascular disorders, such as hypertension and heart failure (HF). One of the aims of PGx studies of adrenoreceptors is the personalization of β-blocker therapy. In this review, we have described biological and clinical impacts on genetic variants of adrenoreceptors, some of which have showed clear association with the reduction in heart rate and blood pressure in response to β-blockers. Beyond anti-hypertension therapy, PGx of adrenoreceptors would contribute to the individualization of pharmacotherapy against HF.